Phase II study of cabazitaxel as 2nd-line treatment in patients with HER-2 negative metastatic breast cancer previously treated with taxanes.
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 31 Jul 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated